Although not an approved therapy, nebulised hypertonic saline (HS) is widely used in CF. Based largely on a single study, various consensus guidelines provide qualified support for HS using 7% b.i.d., but not at a lower concentration or frequency [1]. We sought to gain an understanding of patterns of HS use in a large cross-section of CF physicians. Methods: Specialist physicians in the USA, UK and the EU, currently treating respiratory disease in 20 patients (ages 6+) suffering from CF were asked to participate. Consenting physicians were asked to complete a questionnaire regarding use of HS in their patients with CF. Results: 200 physicians in the USA, UK, and EU were recruited. Collectively, these clinicians had a case-load of 10,600 patients with CF ( 18 years = 77%). Most physicians used HS although the proportion of patients treated varied by region from 30% to 53% and HS concentrations ranged from <3% to >10%. The highest use of 3% HS was in the USA (50%). In the EU overall, 40% patients were administered 6−7% HS concentrations irrespective of treatment frequency, 46% patients had therapy prescribed b.i.d. irrespective of HS concentrations and 16% pts were prescribed at least 6% HS b.i.d.
Background:
Although not an approved therapy, nebulised hypertonic saline (HS) is widely used in CF. Based largely on a single study, various consensus guidelines provide qualified support for HS using 7% b.i.d., but not at a lower concentration or frequency [1] . We sought to gain an understanding of patterns of HS use in a large cross-section of CF physicians. Methods: Specialist physicians in the USA, UK and the EU, currently treating respiratory disease in 20 patients (ages 6+) suffering from CF were asked to participate. Consenting physicians were asked to complete a questionnaire regarding use of HS in their patients with CF. Results: 200 physicians in the USA, UK, and EU were recruited. Collectively, these clinicians had a case-load of 10,600 patients with CF ( 18 years = 77%). Most physicians used HS although the proportion of patients treated varied by region from 30% to 53% and HS concentrations ranged from <3% to >10%. The highest use of 3% HS was in the USA (50%). In the EU overall, 40% patients were administered 6−7% HS concentrations irrespective of treatment frequency, 46% patients had therapy prescribed b.i.d. irrespective of HS concentrations and 16% pts were prescribed at least 6% HS b.i.d. Conclusions: This large survey of HS in patients with CF has confirmed that HS is widely at a range of concentrations and frequencies, primarily as chronic therapy. This study did not explore the basis of the differences in use and it is unclear if further standardisation of dosing strategies is required or warranted.
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[ Objectives: The objective of this study was to assess the compliance of a multidisciplinary cystic fibrosis (CF) clinic at a tertiary paediatric centre with international best practice guidelines and compare with international data. Methods: We compared the percentage of cases attending our CF clinic that complied with 7 clinical care guidelines recommended by the CF Foundation (CFF) (USA). We then compared our results to data reported by the CFF. We also assessed adequacy of clinic consultations with members of the multidisciplinary CF team as recommended by the CF Trust (UK). Results: The percentage of the 90 patients attending our centre who met guidelines was similar or superior to the figures reported by the CFF in 2010 as follows; 4 clinic visits 98% (vs 63% CFF), 4 respiratory cultures 95% (vs 45% CFF), 2 pulmonary function tests if 6 years old 98% (vs 82%), influenza vaccine if 6 months old 96% (vs 73% CFF), fat-soluble vitamin levels measured 94% (vs 81% CFF), oral glucose tolerance test if 10 years old 94% (vs 19% CFF) and serum liver enzyme measurement 94% (vs 72% CFF). The vast majority of patients received consultations with the multidisciplinary CF team as recommended by the CF Trust as follows: full care patients reviewed every 3 months by CF nurse specialist (95%), physiotherapist (85%), dietician (94%) as well as access at each clinic to a clinical psychologist (91%) and social worker (88%) if needed. Our clinic does not however have routine access to a specialist CF pharmacist. Conclusion: The majority of patients attending a tertiary paediatric CF clinic in this study receive care in accordance with international best practice guidelines. The other 14 received organs from brain-dead donors (BD). Age and gender of recipients and donors was equivalent in both groups. The PaO2/FiO2 ratio was better in the BD group (499 vs 357, p = 0.01). Cold ischemic time did not differ in both groups (181 minutes for the first lung and 275 min for the second lung in the BD group vs 194 min and 298 min in the NHBD group, p = 0.72 and 0.57 respectively). Operating bleeding is equivalent in both groups (p = 0.69). We do not observe a significant difference in the duration of intubation despite a trend of longer duration of intubation in the BD group (90 h vs 39 h, p = 0.73) or for the stay in intensive care and hospitalization. Changes in lung function at 1, 3, 6 and 12 months are equivalent in both groups. Conclusion: The lungs harvested from non-heart-beating donors seem to behave the same way as those of BD donors in medium term. But patients with cystic fibrosis are a young population with a high life expectancy. The long-term results of transplantation of these organs are to follow.
Lung transplantation in cystic fibrosis with donation from non-heart-beating donors: early transplant outcomes in a single centre

